Two widely used analogs of nicotinamide and nicotinic acid are 6-aminonicotinamide and 6-aminonicotinic acid (Fig. 1) . In coliform bacteria, these analogs have been useful in selecting for mutants in pyridine nucleotide metabolism (5, 8, 10) . The analogs inhibit growth of wildtype bacteria; this inhibition is corrected by the addition of either nicotinic acid or nicotinamide to the medium, suggesting that the analogs mimic these normal pyridine metabolites and thereby interfere with metabolism. The generally accepted pathway of pyridine nucleotide synthesis, utilization, and recycling is presented in Fig. 2 .
Nicotinamide (or its analog 6-aminonicotinamide) must be deamidated to nicotinic acid (or 6-aminonicotinic acid) before it can be converted to NAD and NADP (or 6-aminonicotinamide adenine dinucleotide [6- aminoNAD] and 6-aminoNADP). It is thought that the toxic effects of the analogs are due to abnormal behavior of these final cofactors. Thus, pncA mutants, defective in deamidation of nicotinamide or its analog, are resistant only to 6-aminonicotinamide; pncB mutants are resistant to both 6-aminonicotinic acid and 6-aminonicotinamide since this step is required to metabolize both analogs. Thus, by the addition of the appropriate analogs to selection media, it has been possible to select and identify pncA or pncB mutants (8) .
In this study, we have isolated a variety of new mutant types that are 6-aminonicotinamide resistant, but that do not have standard mutations at either the pncA or the pncB locus. We have also more directly tested the hypothesis (5) that these analogs exert their bacteriostatic effects by being metabolized by the enzymes of the Preiss-Handler pathway (16) to 6 aminoNAD. We demonstrate that 6-aminonicotinamide-resistant mutants make a lower proportion of 6-aminoNAD to normal NAD than do sensitive strains.
MATERIALS AND METHODS
Bacterial strains. All strains used in this study and their sources are listed in Table 1 . All strains are derived from Salmonella typhimurium LT2.
Media. The E medium of Vogel and Bonner (20) , supplemented with 0.2% dextrose, was used as minimal medium. Alternative carbon sources were supplemented to 0.2% in E medium lacking citrate (17) . Difco nutrient broth (8 g/liter), with NaCl added (5 g/liter), was used as rich medium. To TnlO mutagenesis. A culture of wild-type S. typhimurium strain LT2 was transduced to tetracycline resistance (Tet9 on rich medium by using donor phage grown on a pool of over 10,000 randomly isolated TnJO insertion mutants (6, 13) . These Tetr transductants were replica printed to minimal agar containing 50 ,ug of 6-aminonicotinamide per ml and 10 mM ethylene glycol-bis(3-aminoethyl ether)-N,N-tetraacetic acid, and also to nutrient broth-tetracycline agar. Transductant colonies resistant to 6-aminonicotinamide were purified on green agar, and P22 phage-sensitive colonies were saved. P22 10 ,uCi/ml, 0.8 Ci/mol) until the optical density was 0.5. The culture was centrifuged at 7,500 rpm for 10 min in an RC2B Sorvall centrifuge with an SS34 rotor. Cells were washed once with E medium containing unlabeled 6-aminonicotinamide (100 ,ug/ml) and were suspended in 10 ml of E medium containing 0.2% glucose and 100 ,ug of 6-aminonicotinamide per ml. After 10 min of TR5987  TR6082  TR6416  TR6417  TR6418  TR6465  TR6466  TR6467  TR6480  TR6481  TR6482  TR6483  TR6484  TR6485  TR6486  TR6487  TR6488  TT627  TT628  TT629  TT6195  TT61%  TT6200  TT6203  TT6204  TT6205  TT6206  TT6207  TT6208  TT6209  TT6210  TT6211  TT6213  TT6214  TT6215  TT6216  TT6218  TT6221  TT6222  TT6223  TT6224  TT6226  TT6230   TT6581   TT6974  TT6975  TT6976  TT6977  TT6978  TT6979  TT6980  TT6981  TT6982  TT6983  TT6984  TT6985  TT6986  T17247  TT8052  T18053  TT8054 a 6ANr, 5412 to remove cell debris. The supernatant was neutralized with 1 M Tris (pH 8) and diluted to 1 ml with 0.01 M Tris (pH 8). A commercial preparation of bacterial alkaline phosphatase (Worthington Diagnostics; BAP-C, 10 ,u) was added, and the mixture was incubated for 15 min at 37°C. Then, a second sample of BAP-C was added, and the mixture was incubated for an additional 15 min at 37°C. The phosphatase-treated extract was purified by chromatography on a diethylaminoethyl Sephadex column (2.5 by 25 cm). The column was washed with 5 mM ammonium acetate before the cell extract was applied. After application, elution was carried out with 30 ml each of 0.005, 0.01, 0.02, 0.07, 0.1, and 0.2 M ammonium acetate. Samples (0.2 ml) from each fraction (-5 ml, total) were counted in Aquasol to locate radioactivity. The labeled NAD and 6-aminoNAD were eluted with 0.07 M ammonium acetate.
Samples (0.06 ml) were taken from the fractions with maximum radioactivity and pooled. The pool was applied to DE81 paper including AMP, NMN, NAD, 6-aminonicotinamide, and nicotinamide as markers, and chromatography was carried out by using 0.25 M ammonium bicarbonate to develop the chromatogram. Although NAD and 6-aminoNAD essentially overlap on the diethylaminoethyl Sephadex column, they are well resolved on diethylaminoethyl paper under these conditions. Preparation of cell extracts. A culture of either S. typhimurium LT2, the pncA strain TT6195, or the pncX strain TT6196 was grown in E medium plus glucose to an absorbance of 0.8 at 650 nm. The cells were harvested by centrifugation and washed twice with E medium, and the cell pellet was suspended in 2 ml of 0.05 M phosphate buffer (pH 8). The cells were broken by the use of a French press. For assays of enzymatic activity, a 0.1-ml sample of each cell extract obtained was used.
Assay for conversion of nicotinamide to nicotinic acid. To assay for conversion of radioactive nicotinamide to nicotinic acid, an acid extract or culture supernatant was spotted on DE81 paper. The chromatogram was developed with 0.25 M ammonium bicarbonate for 4 to 5 h. Nicotinamide and nicotinic acid markers (10 mg/ ml) were spotted, the chromatogram was cut into 1-cm strips, and the strips were counted on an L200 Beckman scintillation counter with a toluene-based scintillation fluid.
RESULTS
Screening for 6-aminonicotinamide-resistant mutants. The use of pyridine nucleotide analogs 6-aminonicotinamide and 6-aminonicotinic acid has permitted isolation of pncA and pncB mutants. These mutants are resistant to inhibition by the analog because they are unable to convert exogenous nicotinamide to NAD. To obtain 6-aminonicotinamide resistance mutations that are distinct from classes previously characterized, analog-resistant mutants were selected which retain the ability to use exogenous nicotinamide as a precursor for NAD.
In the first screen, 6-aminonicotinamide-resistant mutants were isolated by using transposon TnWO insertion mutagenesis (see above). Since analog resistance is due to TnWO insertion into a gene, the resistance marker could be transduced into other strains by selecting for inheritance of the TnJO-encoded tetracycline resistance. When 6-aminonicotinamide resistance TnWO insertions were introduced into a nadB strain, the expected pncA: :TnJO and pncB: :TnJO insertion mutants were observed (by their failure to utilize nicotinamide as a pyridine source). In addition, a new class of mutants was seen. This class (class A) is resistant to 6-aminonicotinamide and sensitive to 6-aminonicotinic acid; in this respect it is similar to pncA mutants. However, when a class A mutation is introduced into a nadB strain the resulting transductants retain the ability to use nicotinamide as an exogenous pyridine source. Thus class A mutations have not caused complete loss of pncA function.
In a second experiment, spontaneous 6-aminonicotinamide-resistant mutants (not TnlO generated) were selected. In this screen no strains with class a resistance mutations were isolated; however, along with the expected pncA and pncB mutants, an additional class was isolated. These new mutants are resistant to both 6-aminonicotinamide and 6-aminonicotinic acid (as are pncB mutants), but when an nadA::TnJO mutation is introduced into these strains, they retain the ability to utilize nicotinamide and nicotinic acid as exogenous pyridine sources.
Finally, a third screening procedure was carried out, looking for mutants with temperaturesensitive lethal mutations and which are resistant to 6-aminonicotinamide on minimal medium at the permissive temperature. Mutants resistant to 6-aminonicotinamide were selected at 30°C and were then screened for their ability to grow at the high temperature (42°C). Some of the resulting temperature-sensitive mutants grew at the high temperature in the presence of nicotinamide (class B), whereas the rest did not. Mutants in which temperature sensitivity is not corrected by nicotinamide proved to have a mutation in the same gene as several of the spontaneous mutations described above. This type of mutation was placed in class C.
In summary, class A mutant were all 6-aminonicotinamide resistant, but sensitive to 6-aminonicotinic acid. Class B and class C mutants were resistant to both 6-aminonicotinamide and 6-aminonicotinic acid. Only TnWO insertion mutations fell in the class A group. The temperaturesensitive mutants were found for both the class linkage varied between 26 and 92% depending on the class A allele used. The ability of these strains to convert nicotinamide to nicotinic acid was tested in vivo. The experiment shown in Fig. 2 demonstrates that class A mutants did not convert exogenous nicotinamide to nicotinic acid (in the medium) at a detectable level; a corresponding experiment with a wild-type strain shows rapid excretion of nicotinic acid produced from exogenous nicotinamide. However, some conversion of nicotinamide to nicotinic acid must occur in these cells, since strains harboring a class A resistance mutation and an nadA mutation can utilize nicotinamide as a source of the pyridine ring. Enzymatic assays for nicotinamide deamidase were carried out on cell extracts to determine how much enzyme was actually present in these mutants. The deamidase activity in a class A mutant was compared with that in isogenic pncA and wild-type strains. The class A mutant had detectable activity, but that activity was about 10-fold lower than the activity of nicotinamide deamidase detected in wild-type cells. However, the deamidase levels are at least 10-fold higher than in a pncA strain; the latter had no detectable activity (Table 2 ). These results suggest that the class A TnWO insertions reduce, but do not eliminate, expression of the nearby pncA gene. This could be due to substitution of the TnlO outward promoter (4) for the normal pncA promoter. Alternatively, the insertions may inactivate a positive regulatory gene for pncA. These possibilities are currently being tested.
We have tentatively designated all class A mutants pncX; whether these are all mutated in the same gene is not clear. Similar mutants have Fig. 3 and 4 .
As shown in Fig. 3 , a class C mutant has a much lower ratio of 6-aminoNAD to NAD than does the wild type. Similar results are found for the class B mutants. However, all of these measurements are complicated by the fact that different ratios of 6-aminoNAD to NAD are obtained depending on the precise labeling protocol used. It appears that the ratios change as a function of time of labeling because 6-amino-NAD turns over much less rapidly than NAD. Thus, the specific activity of 6-aminoNAD increases with respect to NAD the longer the labeling period. This effect is shown in Fig. 4 . As shown in Table 3 Fig. 3 and 4 . 6ANr, 6-aminonicotinamide resistant.
higher ratio of NAD to 6-aminoNAD than does the parental 6-aminonicotinamide-sensitive strain.
We conclude on the basis of these results that the 6-aminonicotinamide resistance of class B and class C mutants is consistent with a higher ratio of normal NAD to 6-aminoNAD in the presence of the precursor 6- Transduction experiments show that the class B mutations all map at the nadB locus. None mapped near the nadA or nadC locus (9, 10) . A large number of class B mutants were also generated by localized mutagenesis of the nadB region (see above). A fine structure mapping of these mutations has shown that all class B mutations examined map within the nadB gene (B. Cookson and J. Roth, unpublished data).
The dominance of the nadB (6-aminonicotinamide resistance) mutations to a wild-type allele was shown in chromosomal duplications of the nadB region. Strain TR5129 carries a tandem chromosomal duplication of the nadB region, which can be selectively maintained by growth on histidinol. Selection and manipulation of these duplications is described elsewhere (1). This strain was transduced to Tetr with phage grown on an nadB (6-aminonicotinamide resistant) host harboring a TnJO insertion close to the nadB gene. Approximately 65% of all Tetr transductants were made resistant to 6-aminonicotinic acid. The high frequency of 6-aminonicotinamide-resistant colonies indicates that the nadB (6-aminonicotinamide resistance) allele is dominant over the nadB+ phenotype. To insure that the strains actually carried duplications and were heterozygous, containing both the nadB (6- aminonicotinamide resistant) and the wild-type allele, the phenotype of spontaneous haploid segregants was determined. The duplications tested were grown overnight on nutrient broth and then streaked on minimal medium containing histidinol and low histidine. Parent duplication types form large colonies on this medium, and haploid segregants form small colonies. Twenty-five colonies were picked, patched, and printed to minimal medium, minimal medium plus histidinol, and minimal medium plus histidinol and 6-aminonicotinic acid. Both 6-aminonicotinamide-sensitive and 6-aminonicotinamide-resistant strains were found among the haploid segregants, insuring that the strains actually harbored both nadB+ and nadB (6-aminonicotinamide resistance) alleles of the locus.
Characterization of class C mutants. All mutants with lethal temperature-sensitive and 6-aminonicotinamide resistance mutations and which were not rescued by the addition of exogenous nicotinamide or nicotinic acid were class C mutants. Hfr mapping showed that these mutations mapped between min 12 and 22 on the S. typhimurium chromosome (between purE and pyrC) ( (Fig. 5) . DISCUSSION The nicotinamide and nicotinic acid analogs 6-aminonicotinamide and 6-aminonicotinic acid are believed to cause bacteriostasis because the 6-aminoNAD formed from these analogs interferes with many NAD-utilizing reactions in general metabolism. Previous studies indicate that 6-aminoNAD cannot act as an electron acceptor for several dehydrogenases (7). Thus, Cobb and co-workers suggested that for 6-aminonicotinamide to cause growth inhibition, it must first be converted to 6-aminoNAD (5 The second class of mutants found, with mutations mapping in the nadB gene, are of considerable interest. The nadB product is involved in the endogenous biosynthetic pathway and would not be directly involved in the conversion of 6-aminonicotinamide to 6-aminoNAD. The simplest explanation for the dominance of the 6-aminonicotinamide-resistance mutations in the nadB gene is that the nadB enzyme, L-aspartate oxidase, is regulated by feed back inhibition, and that the 6-aminonicotinamide-resistant mutants are defective in such feed back regulation (14) . We suggest that 6-aminonicotinamide is not only a precursor for the bacteriostatic metabolite 6-aminoNAD, but may, in addition, depress synthesis of normal NAD by direct or indirect feedback on endogenous synthesis. It is known that Escherichia coli, given a choice between an exogenous precursor and endogenous synthesis, will preferentially use the exogenous source of the pyridine ring. How this regulation is achieved is not known in detail. The results with S. typhimurium suggest, however, that the nadB gene is an important component of the regulation. If 6-aminonicotinamide normally caused inhibition of nadB function, then endogenous synthesis would be depressed and the levels of 6-aminoNAD would be very high compared with normal NAD. However, in the 6-aminonicotinamide-resistant nadB mutants, the presence of 6-aminonicotinamide apparently does not cause as great a depression of endogenous synthesis. As a consequence, high levels of endogenous NAD synthesis continue even in the presence of the analog accounting for the relative resistance of such strains. The isolation of these mutants in the nadB locus, but not in the nadA or nadC locus, indicates that nadB is the primary site of regulation of endogenous synthesis. Reports in the literature indicate that NAD inhibits nadB function (11, 14) . However, a detailed comparison of wild-type and mutant nadB gene products will be necessary to definitively identify which metabolite is relevant in this regulation.
The third class of 6-aminonicotinamide resistance mutations are in a previously undefined genetic locus. We have presented evidence that these do not fall in any of the known loci for nad or pnc genes. The 6-aminonicotinamide-resistant mutations that are also temperature-sensitive lethal mutations map at this locus. The precise map location of these mutations and the precise biochemical function affected are currently being determined. Our preliminary results strongly suggest that mutants with mutations at this locus (which we have designated nadD) are defective in the enzyme NaAD pyrophosphorylase, which converts NaMN to NaAD (Fig. 5) . A comprehensive study of these nadD mutants is currently under way.
The in vivo determination of 6-aminoNAD demonstrates that resistant strains have a lower 6-aminoNAD/NAD ratio than sensitive strains. These results support the suggestion of Cobb and co-workers (5) that it is the 6-aminoNAD and 6-aminoNADP analogs that account for bacteriostatic effects in vivo. In this study, we also obtained evidence that 6-aminoNAD turns over much more slowly than does the normal dinucleotide. Thus, it appears that in addition to its well known inability to act as an electron acceptor in reactions catalyzed by a number of dehydrogenases, 6-aminoNAD is also a poor substrate for enzymes that catalyze the degradation of NAD in vivo. This raises the possibility that the limiting reaction for bacterial growth may not be a dehydrogenase, but rather one in which NAD is a substrate such as DNA ligase (15) .
The results of this study suggest that any mutation that leads to a lower 6-aminoNAD/ NAD ratio may confer some degree of resistance to the analog. The most easily isolated mutants have mutations at the pncA and pncB loci that completely block formation of 6-aminoNAD from 6-aminonicotinamide. In this work, the mutants we have isolated have mutations that do not completely block 6-aminoNAD formation, but in different ways, cause a relative decrease in the level of the analog compared to the normal dinucleotide in vivo. These mutants, as well as perhaps even more subtle 6-aminonicotinamideresistant phenotypes, should not only be useful in identifying new genetic functions affecting pyridine nucleotide metabolism, but also in unscrambling the regulatory features of the complex pathways of the biosynthesis, and the breakdown and turnover of NAD and NADP. ACKNOWLEDGMENTS This work was supported by Public Health Service GM25654 from the National Institutes of Health. K.T.H. was supported by Public Health Service predoctoral training grant T32-GM07531 from the National Institutes of Health. LITERATURE CITED 1. Anderson, R. R., and J. R. Roth. 1978 
